Galecto Corp - GLTO Quarterly EPS earnings growth

Galecto Corporation - graphic logo of issuer GLTO

Galecto, Inc. (GLTO) management is pivoting its strategic direction, focusing on the search for new assets following failed trials. The quarterly change in earnings per share confirms this shift in course, recording the metric at 30.10. Business dynamics depend on scientific breakthroughs in cancer treatment rather than economic factors. The current portfolio restructuring and workforce optimization require close attention from investors.

Galecto (GLTO) - Year-over-year earnings per share growth for the last twelve months from 07/04/2022 to 03/10/2026

Financial and market metric breakdowns for Galecto Corporation (GLTO)

- share price and consensus valuation forecast:
Stock Quotes Galecto|GLTO - Analyst Forecast Prices
- issuer market value details:
Market Capitalization Galecto Corp|GLTO - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Galecto|GLTO - Company Book Value|Market Value to Book Value Ratio galecto.com|GLTO - Company Assets
- debt and liquidity data:
Debt to Equity Galecto, Inc.|GLTO - Long-Term Debt to Equity|Short-Term Debt to Capital Galecto, Inc.|GLTO - Company Total Debt Obligations|Debt to Book Capitalization Ratio Galecto Corp|GLTO - Long-Term Debt Volume|Company Short-Term Debt Galecto|Quick Ratio galecto.com
- earnings and valuation multiples indicators:
GLTO - Annual Net Income|Projected Future Earnings Galecto, Inc.|GLTO - P/E Multiple|Future Price to Earnings Galecto Corp|GLTO - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Galecto Corp|GLTO - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Galecto|GLTO - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months galecto.com|GLTO - Net earnings per one share growth for the current year|Net earnings per share growth forecast for next year Galecto, Inc.
Analysis of all company metrics:Galecto, Inc.
Manufactured product of Galecto Corporation

To minimize investment risks, it is necessary to analyze the dynamics of net income per share, which reflects the rate of capital change amid global liquidity shifts. By studying the volatility of the quarterly EPS, an investor assesses the monetization efficiency of Galecto, Inc. (GLTO) developments in galectin protein inhibition, which is critical for valuing the creation of alternative-free treatment methods for organ fibrosis.

Competitors of Galecto, Inc. (GLTO)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Corp|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MTSR (metsera.com)|Year-over-year earnings per share growth for the last twelve months MoonLake MLTX|Crinetics Pharmaceuticals, Inc. (CRNX) - Earnings per share growth in annualized terms for the last twelve months|NAMS - Year-over-year earnings per share growth for the last twelve months|SLNO: Year-over-year earnings per share growth for the last twelve months|FOLD: Quarterly EPS earnings growth|ETNB - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Agios Pharmaceuticals, Inc.|Structure Therapeutics Inc (GPCR) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months MiMedx Group (MDXG)|Year-over-year net earnings per share growth for the last 12 months Rezolute Bio RZLT|Quarterly EPS earnings growth LXRX (Lexicon Pharmaceuticals)|Net earnings per share growth for the trailing year mbxbio.com|Altimmune - Quarterly EPS earnings growth|AARD - Quarterly EPS earnings growth|Sagimet (SGMT) - Year-over-year earnings per share growth for the last twelve months|BIOA (BioAge Labs, Inc) - Year-over-year earnings per share growth for the last twelve months|BMEA (Biomea Fusion, Inc.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Quince QNCX|Quarterly EPS earnings growth GUTS|Year-over-year net earnings per share growth for the last 12 months vtvtherapeutics.com VTVT|Agape ATP - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months PLUR (Pluristem Therapeutics)|SYBX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months lipocine.com|MTNB (matinasbiopharma.com) - Year-over-year net earnings per share growth for the last 12 months|sprucebiosciences.com - Year-over-year earnings per one share growth for the last 12 months|CTCX (Carmell Corp) - Quarterly EPS earnings growth|Lumos Therapeutics (LUMO) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Organovo Holdings, Inc. (ONVO)|radiuspharm.com - Year-over-year earnings per share growth for the last 12 months